Personalized tumor-informed circulating tumor DNA monitoring for early detection of recurrence in postoperative pancreatic cancer

BackgroundUp to 80% of patients with resected pancreatic cancer experience recurrence within 2 years. We evaluated the feasibility and accuracy of a personalized, tumor-informed circulating tumor DNA (ctDNA) test for the early detection of recurrence risk during long-term postoperative surveillance....

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Jingjing Chen, Lu Zou, Xinyuan Bai, Fan Tong, Jiayao Ni, Haochen Tang, Yaru Liu, Xiang Kong, Jiani Yin, Fufeng Wang, Huizi Sha, Fanyan Meng, Juan Du
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Frontiers Media S.A. 2026-01-01
Sarja:	Frontiers in Oncology
Aiheet:	adjuvant chemotherapy circulating tumor DNA dynamic ctDNA minimal residual disease pancreatic cancer
Linkit:	https://www.frontiersin.org/articles/10.3389/fonc.2026.1745466/full
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!